Upload Avatar (500 x 500)
Zou Zhengyun
Medical School
Nanjing University
Jiangsu
Language: English, Chinese, French
Immunotherapy
Malignant Tumors
Precision Medicine
Melanoma
Clinical Research
Biological Therapy
T Cells
Pd-1 Gene
Neoantigen
Cancer Treatment
Areas of Focus
- Precision Immunotherapy for Malignant Tumors
- Basic and Clinical Research on Malignant Melanoma
Work Experience
- Current - Nanjing University Medical School Affiliated Drum Tower Hospital - Chief Physician, Associate Professor, Doctoral Supervisor
- Current - Nanjing Drum Tower Hospital Jiangbei International Hospital - Director of Comprehensive Office
- Current - Nanjing University Medical School Affiliated Drum Tower Hospital - Deputy Director of Oncology Center
- Current - Nanjing University Medical School Affiliated Drum Tower Hospital - Head of Biological Therapy Group
- Current - Nanjing University Medical School Affiliated Drum Tower Hospital - Leader of Subspecialty in Malignant Melanoma and Hepatobiliary and Pancreatic Cancer
Academic Background & Achievements
- Medical Doctor: Nanjing University Medical School
- Visiting Scholar: University of Texas Health Science Center at Houston
- Visiting Scholar: Paul Brousse Hospital, Paris
- Special Reviewer: Chinese Journal of Cancer Biotherapy
- Editorial Board Member: Journal of Tumor Nutrition and Metabolism
- Editorial Board Member: CSCO Malignant Melanoma Diagnosis and Treatment Guidelines 2019
- First Reviewer: National Natural Science Foundation of China
Publications
- The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases, Corresponding Author, 2019
- iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer, Co-First Author, 2019
- Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors, Co-First Author, 2019
- CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer, Co-First Author, 2016
- Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma, Co-First Author, 2017
- The plasma levels of 12 cytokines and growth factors in patients with gastric cancer, First Author, 2018
- Gambogic acid-loaded PEG-PCL nanoparticles act as an effective antitumor agent against gastric cancer, Co-First Author, 2018
- Multidisciplinary collaboration in gallbladder carcinoma treatment: A case report and literature review, First Author, 2016
- Gastric metastasis from sphenoid sinus melanoma: A case report, Corresponding Author, 2015
Awards
- Jiangsu Province Medical New Technology Introduction First Prize (2017)
- Ministry of Education Science and Technology Progress Award Second Prize (2016)
- Jiangsu Province Science and Technology Award Second Prize (2015)
- Chinese Medical Science and Technology Award Third Prize (2015)
- Jiangsu Medical Science and Technology Award Second Prize (2015)
